| Literature DB >> 18926775 |
Thanyalak Tha-In1, Jagadeesh Bayry, Herold J Metselaar, Srini V Kaveri, Jaap Kwekkeboom.
Abstract
Intravenous immunoglobulin (IVIg) is therapeutically used in a variety of immune-mediated diseases. The beneficial effects of IVIg in auto-antibody-mediated diseases can be explained by neutralization, accelerated clearance and prevention of Fcgamma-receptor binding of auto-antibodies. However, the means by which IVIg exerts therapeutic effects in disorders mediated by cellular immunity have remained enigmatic. Clinical improvements, followed by IVIg treatment, often extend beyond the half-life of infused IgG, thereby indicating that IVIg modifies the cellular immune compartment for a prolonged period. Here, we discuss recent advances in the understanding of different, mutually non-exclusive mechanisms of action of IVIg on cells of the innate and adaptive immune system. These mechanisms might explain the beneficial effects of IVIg in certain autoimmune and inflammatory diseases.Mesh:
Substances:
Year: 2008 PMID: 18926775 DOI: 10.1016/j.it.2008.08.004
Source DB: PubMed Journal: Trends Immunol ISSN: 1471-4906 Impact factor: 16.687